Teachers Retirement System of The State of Kentucky Has $29.11 Million Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Teachers Retirement System of The State of Kentucky lifted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 10.8% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,894,100 shares of the company's stock after acquiring an additional 184,100 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.17% of Teva Pharmaceutical Industries worth $29,112,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Kestra Private Wealth Services LLC lifted its position in shares of Teva Pharmaceutical Industries by 6.6% during the 1st quarter. Kestra Private Wealth Services LLC now owns 33,598 shares of the company's stock worth $516,000 after purchasing an additional 2,072 shares during the last quarter. Carnegie Lake Advisors LLC increased its position in Teva Pharmaceutical Industries by 23.8% in the 1st quarter. Carnegie Lake Advisors LLC now owns 85,350 shares of the company's stock worth $1,312,000 after buying an additional 16,400 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 1.2% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after buying an additional 300,000 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 12.8% in the first quarter. Victory Capital Management Inc. now owns 3,410,142 shares of the company's stock valued at $52,414,000 after acquiring an additional 386,668 shares during the period. Finally, Burford Brothers Inc. grew its stake in shares of Teva Pharmaceutical Industries by 2.1% in the first quarter. Burford Brothers Inc. now owns 155,876 shares of the company's stock worth $2,396,000 after acquiring an additional 3,189 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Bank of America upped their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, UBS Group cut their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Trading Down 1.4%

Shares of Teva Pharmaceutical Industries stock traded down $0.23 on Friday, hitting $16.08. 12,142,802 shares of the company's stock traded hands, compared to its average volume of 10,336,516. The firm's 50-day moving average price is $17.01 and its two-hundred day moving average price is $16.91. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The stock has a market capitalization of $18.44 billion, a PE ratio of -13.98, a price-to-earnings-growth ratio of 0.94 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The company had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same period in the prior year, the business posted $0.48 EPS. Teva Pharmaceutical Industries's revenue was up 1.9% on a year-over-year basis. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.